- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00447187
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was intended for surgical episcleral placement in the eye.
The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure following penetrating keratoplasty with LX201 implantation. Subjects were to be followed in an outpatient setting for safety and efficacy at 4-6 week intervals for 52 weeks following transplantation surgery.
After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2-year period or until time of implant removal. For subjects in the USA and India, if the implant was removed at any time prior to the 3 year safety follow-up, the subject was to have a final safety follow up visit at 3 months post removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Erlangen, Alemania, 91054
- Augenklinik, Universitat Erlangen-Nurnberg
-
Essen, Alemania, 45122
- Cornea Bank, Universitätsklinikum Essen
-
Kiel, Alemania, 24105
- Klinik fuer Ophthalmologie Campus Kiel
-
Muenchen, Alemania, 80336
- Ludwig Maximilians Universität
-
München, Alemania, 81675
- Augenklinik der Technischen Universität München
-
Wuerzburg, Alemania, 97080
- Augenklinik Wuerzburg
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Cornea Consultants of Arizona
-
-
California
-
Loma Linda, California, Estados Unidos, 92354
- Loma Linda University Health Care
-
Los Angeles, California, Estados Unidos, 90033
- USC Doheny Eye Institute
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Bascom Palmer Eye Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory Eye Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois at Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Price Vision Group
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21218
- The Eye Center at Union Memorial Hospital
-
Baltimore, Maryland, Estados Unidos, 21287
- Wilmer Eye Institute, Cornea Service
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- New England Eye Center
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- W.K. Kellogg Eye Center - University of Michigan
-
-
Minnesota
-
Bloomington, Minnesota, Estados Unidos, 55431
- MN Eye Consultants, P.A.
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Tauber Eye Center
-
St. Louis, Missouri, Estados Unidos, 63141
- Ophthalmology Associates
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07103
- UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Mount Sinai School of Medicine
-
New York, New York, Estados Unidos, 10003
- New York Eye and Ear Infirmary
-
Rockville Center, New York, Estados Unidos, 11570
- Ophthalmic Consultants of Long Island
-
Slingerlands, New York, Estados Unidos, 12159
- Cornea Consultants of Albany
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University Eye Center
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals Case Medical Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75231
- Cornea Associates of Texas
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Eye Associates NW
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:
- ≥ 1 quadrant deep corneal vascularization
- verifiable history of graft failure due to rejection
- position of graft is < 1 mm from the limbus
Exclusion Criteria:
- Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
- Schirmer's test ≤ 5 mm in 1 minute
- Clinical evidence of limbal stem cell deficiency
- History of or active herpes simplex virus keratitis or other acute corneal infection
- Subjects who have had > 3 failed grafts in the study eye
- Uncontrolled glaucoma as evidenced by an intraocular pressure of >21 mmHg while on maximal medical therapy
- Clinically suspected or confirmed ocular lymphoma
- Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
- Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)
- Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
- Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
- History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous exposure or known contraindication to administration of cyclosporine
- Recipients of a solid organ transplant
- Currently pregnant or lactating
- Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
- Severe anemia (hemoglobin < 6 g/dL), leukopenia (white blood cell count [WBC] < 2500 mm3), thrombocytopenia (platelet count < 80,000 mm3), polycythemia (hematocrit [Hct] > 54% [male] or Hct > 49% [female]) or clinically significant coagulopathy
- Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
- Active peptic ulcer disease
- Co-morbid conditions that require immunosuppression
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Implante LX201 de 0,50 pulgadas
El implante LX201 contenía 30 % de ciclosporina A por peso y 0,50 pulgadas de largo
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Experimental: Implante LX201 de 0,75 pulgadas
El implante LX201 contenía 30 % de ciclosporina A en peso y 0,75 pulgadas de longitud
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Comparador de placebos: Implante placebo de 0,75 pulgadas
Implante de silicona que no contiene ciclosporina A, 0,75 pulgadas de largo
|
El placebo era un implante de silicona de 0,75 pulgadas de largo.
No contenía ciclosporina A
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
graft rejection or graft failure
Periodo de tiempo: 52 weeks
|
52 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Eddy Anglade, MD, Chief Medical Officer, Lux Biosciences, Inc.
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LX201-01
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedades de la córnea
-
University of Texas Southwestern Medical CenterTerminadoEdema corneal secundario a distrofia endotelial cornealEstados Unidos
-
Haag-Streit AGUniversity Hospital Inselspital, BerneTerminado
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...DesconocidoDistrofia endotelial corneal de FuchsEstados Unidos
-
Bausch & Lomb IncorporatedTerminadoAstigmatismo CornealCanadá
-
Walter Reed Army Medical CenterTerminado
-
Innovative MedicalTerminadoTinción cornealEstados Unidos
-
Asociación para Evitar la Ceguera en MéxicoTerminadoEpitelio cornealMéxico
-
Andrasko, Gary, OD, LLCAlcon ResearchDesconocidoTinción corneal | Corneal Epithelial DisruptionEstados Unidos
-
Innovative MedicalTerminadoTinción cornealEstados Unidos
-
EmmecellReclutamientoDisfunción endotélica | Edema corneal | Distrofia de Fuchs | Distrofia endotelial corneal | Queratopatía bullosa | Queratopatía ampollosa pseudofáquica | Disfunción endotelial corneal | Distrofia corneal endotelial de Fuchs | Descompensación endotelial corneal moderadaEstados Unidos
Ensayos clínicos sobre LX201
-
Lux Biosciences, Inc.TerminadoTrasplante de córnea | Rechazo de injerto de córneaEstados Unidos, Alemania